These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 15731164

  • 1. Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor.
    Zeng Y, Yokohira M, Saoo K, Takeuchi H, Chen Y, Yamakawa K, Matsuda Y, Kakehi Y, Imaida K.
    Carcinogenesis; 2005 Jun; 26(6):1109-16. PubMed ID: 15731164
    [Abstract] [Full Text] [Related]

  • 2. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model.
    Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS.
    Cancer Res; 2002 Mar 01; 62(5):1370-6. PubMed ID: 11888907
    [Abstract] [Full Text] [Related]

  • 3. Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model.
    Cho YM, Takahashi S, Asamoto M, Suzuki S, Tang M, Shirai T.
    Prostate Cancer Prostatic Dis; 2007 Mar 01; 10(4):378-83. PubMed ID: 17457304
    [Abstract] [Full Text] [Related]

  • 4. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent.
    Asamoto M, Hokaiwado N, Cho YM, Takahashi S, Ikeda Y, Imaida K, Shirai T.
    Cancer Res; 2001 Jun 15; 61(12):4693-700. PubMed ID: 11406539
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
    Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, Shappell SB, Matusik RJ.
    Cancer Res; 2001 Mar 01; 61(5):2239-49. PubMed ID: 11280793
    [Abstract] [Full Text] [Related]

  • 7. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model.
    Raghow S, Kuliyev E, Steakley M, Greenberg N, Steiner MS.
    Cancer Res; 2000 Aug 01; 60(15):4093-7. PubMed ID: 10945615
    [Abstract] [Full Text] [Related]

  • 8. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
    Narayanan BA, Narayanan NK, Pittman B, Reddy BS.
    Clin Cancer Res; 2004 Nov 15; 10(22):7727-37. PubMed ID: 15570007
    [Abstract] [Full Text] [Related]

  • 9. Lack of significant modifying effect of arctiin on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats.
    Zeng Y, Yokohira M, Takeuchi H, Saoo K, Yamakawa K, Matsuda Y, Hosokawa K, Li JQ, Ikeda M, Imaida K.
    Cancer Lett; 2005 May 26; 222(2):145-51. PubMed ID: 15863263
    [Abstract] [Full Text] [Related]

  • 10. Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma.
    Shappell SB, Olson SJ, Hannah SE, Manning S, Roberts RL, Masumori N, Jisaka M, Boeglin WE, Vader V, Dave DS, Shook MF, Thomas TZ, Funk CD, Brash AR, Matusik RJ.
    Cancer Res; 2003 May 01; 63(9):2256-67. PubMed ID: 12727848
    [Abstract] [Full Text] [Related]

  • 11. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
    Narayanan BA, Reddy BS, Bosland MC, Nargi D, Horton L, Randolph C, Narayanan NK.
    Clin Cancer Res; 2007 Oct 01; 13(19):5965-73. PubMed ID: 17908994
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters.
    Furukawa F, Nishikawa A, Lee IS, Kanki K, Umemura T, Okazaki K, Kawamori T, Wakabayashi K, Hirose M.
    Int J Cancer; 2003 Apr 10; 104(3):269-73. PubMed ID: 12569549
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats.
    Fong LY, Zhang L, Jiang Y, Farber JL.
    J Natl Cancer Inst; 2005 Jan 05; 97(1):40-50. PubMed ID: 15632379
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide.
    Shiotani H, Denda A, Yamamoto K, Kitayama W, Endoh T, Sasaki Y, Tsutsumi N, Sugimura M, Konishi Y.
    Cancer Res; 2001 Feb 15; 61(4):1451-6. PubMed ID: 11245450
    [Abstract] [Full Text] [Related]

  • 19. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
    Green JE, Shibata MA, Shibata E, Moon RC, Anver MR, Kelloff G, Lubet R.
    Cancer Res; 2001 Oct 15; 61(20):7449-55. PubMed ID: 11606379
    [Abstract] [Full Text] [Related]

  • 20. Resistance of prostate cancer cell lines to COX-2 inhibitor treatment.
    Wagner M, Loos J, Weksler N, Gantner M, Corless CL, Barry JM, Beer TM, Garzotto M.
    Biochem Biophys Res Commun; 2005 Jul 08; 332(3):800-7. PubMed ID: 15907789
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.